BMS
Research type
Research Study
Full title
Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World (DISCOVER-HCM): United States Prospective Registry Study
IRAS ID
349402
Contact name
Robert Cooper
Contact email
Sponsor organisation
Bristol Meyer Squibb
Duration of Study in the UK
3 years, 0 months, 2 days
Research summary
To evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) in the real-world setting. The registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients with symptomatic obstructive HCM who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment.
Because this is an observational registry study, no medications or other treatments are provided to the participants.
Participation in the study is expected to last eighteen (18) months, with 3 follow-up visits. Eligible will be all patients, willing and able to provide written informed consent form, diagnosis of obstructive HCM, Documented LVEF of ≥55% recorded by TTE, Documented symptoms consistent with NYHA functional class II–III at enrollment or within 6 months prior to enrollment, 18 years old or older.REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
24/EM/0283
Date of REC Opinion
24 Feb 2025
REC opinion
Further Information Favourable Opinion